Co-Payment Increases Result In Gaps In Veterans' Prescription Usage
Fewer veterans filled their prescriptions for cholesterol-lowering drugs after an increase in co-payment costs for prescription drugs, researchers report in Circulation: Journal of the American Heart Association.
In February 2002, the Veterans Administration (VA) increased prescription co-payments from $2 to $7 per 30-day drug supply.
To determine the impact of the co-payment increase on cholesterol-lowering medication adherence, researchers examined the electronic records of 5,604 veterans treated at the Philadelphia Veterans Administration (VA) Medical Center from November 1999 to April 2004.
They compared veterans in the all co-payment group and the some co-payment group with veterans who were exempt from making prescription drug co-payments. The all co-payment group paid co-pays for all drugs and the some co-payment group paid co-pays only for drugs for non-service connected health problems with out-of-pocket expenses capped at $840 per year.
Researchers analyzed the differences in cholesterol-lowering medication adherence during the 24 months before and 24 months after the institution of co-payments. Evidence of veterans having cholesterol-lowering medication 80 percent or more of the time were considered adherent.
• The number of patients who had medications available for more than 80 percent of the time declined by more than 19 percent in both the all co-payment group and the some co-payment group. In comparison, veterans exempt from co-payments, used as controls in the study, had a decline of 12 percent.
• The odds of having a continuous gap without medications for more than 90 days was three times higher among patients in the all co-payment group and twice as high in patients in the some co-payment group when compared to the exempt group.
“The increase in co-payments adversely impacted lipid-lowering medication adherence among veterans,” said Jalpa A. Doshi, Ph.D., lead author of the study and research assistant professor of medicine at the University of Pennsylvania School of Medicine. “Of even greater concern is our finding on the similar adverse effect of the co-payment increase in veterans who are at higher risk for coronary artery disease taking the medications for primary or secondary prevention.”
Statins and other cholesterol-lowering drugs have been shown to reduce the risk of future coronary events and cardiovascular mortality in patients at high risk, Doshi said.
“It is concerning to see that the increase in co-payments adversely affected the use of these usually long-term medications, especially since the prevalence of heart disease is higher in the VA population than in the general population,” Doshi said. “These weren’t just short gaps interspersed between lipid-lowering medication refills, but continuous gaps for 90 days or more.”
The study did not look at the possible increase in use of medical care due to the lack of cholesterol-lowering drugs. Other studies have shown that not taking medications for chronic diseases increases healthcare costs.
“Policymakers need to realize that the one-size-fits-all approach in designing cost-sharing policies can adversely impact high-risk patient groups,” Doshi said. “This seemingly small increase from $2 to $7 more than tripled the out-of-pocket costs for veterans, who were more likely to have a lower income than the patients in the private sector.”
The VA should at least consider charging lower co-payments for generic drugs than for the brand-name prescription drugs, Doshi said. “Right now the VA charges a flat co-payment for a 30-day prescription, whether it is generic or a brand-name drug. This is particularly relevant in the case of lipid-lowering drugs such as statins, wherein two brand drugs became available as generics in 2006 and are available at significantly lower prices.”
She said a more-promising approach is a “value-based insurance design” method that would link co-payments to the patient’s need with lower co-payments for drugs with higher expected therapeutic benefit and higher co-payments for drugs with lower therapeutic benefit.
The co-payment was increased from $7 to $8 in 2006, and with present budget constraints, it’s likely that the co-payment will be further increased, Doshi said.